Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AdMSC

Phase 2Small molecule

UUniversity Hospital, Toulouse

AdMSC is one of 44 small molecule programs targeting Scleroderma. It is currently in Phase 2.

4

Indications

4

Total Trials

4

Active Trials

43

Competitors

Pipeline

Status by Indication[3][1]

Indication

SclerodermaRecruiting

Systemic SclerodermaNot yet recruiting

Early Alzheimer's DiseaseRecruiting

Crohn's FistulaRecruiting

SclerodermaPhase 2

Recruiting

Systemic SclerodermaPhase 2

Not yet recruiting

Early Alzheimer's DiseasePhase 2

Recruiting

Crohn's FistulaPhase 2

Recruiting

Competition

Competitive Landscape

22 competitors in Systemic Scleroderma

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Crestor

Remodulin

United Therapeutics

Buspar

Bristol-Myers Squibb

Cellcept

Adempas

Tracleer

Johnson & Johnson

Cialis

Medrol

Gleevec

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Early Alzheimer's Disease

NCT06775964

Phase 2Recruiting

Scleroderma

NCT04356755

Q3 2027

Phase 1/2Recruiting

Crohn's Fistula

NCT06636032

Q3 2028

Phase 2Not yet recruiting

Systemic Scleroderma

NCT07326033

Clinical

Trials by Indication[1]

Early Alzheimer's Disease1 trial

Stem Cell Therapy for Early Alzheimer's Disease

Recruiting·PPaul E Schulz·Phase 1/2·NCT06775964·12 enrolled

Scleroderma1 trial

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT04356755·32 enrolled

Crohn's Fistula1 trial

Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula

Recruiting·UUniversity Hospital, Toulouse·Phase 1/2·NCT06636032·9 enrolled

Systemic Scleroderma1 trial

Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients With Systemic sclEroderma

Not yet recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT07326033·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AdMSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AdMSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AdMSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Toulouse

Related News